Oppenheimer lowered the firm’s price target on Fulcrum Therapeutics to $20 from $26 and keeps an Outperform rating on the shares following FTX-6058’s clinical hold. The firm thinks the most likely explanation is that the agency didn’t like something it saw in the last IND update. It may have been something as simple as an abnormal blood count, but as the Oppenheimer’s expert emphasized, right now the agency is hypersensitive to even the slightest abnormality in sickle cell disease. With that in mind, the firm thinks Friday’s selloff may be overdone, but is lowering its target based on added regulatory risk and development timelines.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FULC:
- Fulcrum Therapeutics downgraded to Underperform from Neutral at BofA
- Fulcrum clinical hold ‘gut punch for shares,’ says Oppenheimer
- Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
- Fulcrum Therapeutics announces clinical hold on FTX-6058 in SCD
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)